The Development and Validation of Technology for Time Critical Genomic Testing (DEVOTE) Programme

生物标记物是一种可以从人体测量的化学物质或信号，有助于诊断疾病或预测未来的健康状态。生物标记物通常用于医疗保健以指导患者管理，但在临床相关生物标记物的发现与其在帮助患者的常规实践中的实施之间存在着重大的翻译瓶颈。对于遗传生物标记物尤其如此，它被定义为我们的遗传密码的变化，这些变化容易导致疾病或预测治疗结果。其中许多与药物遗传学有关，即我们的遗传密码的变化影响我们对药物的反应。目前，基因检测速度太慢，无法指导日常实践中的处方。传统的基因检测需要几周或几个月的时间才能恢复，这太慢了，无法在大多数临床环境中使用。然而，新技术有可能改变这一点。生物技术公司面临的挑战是了解如何在给定的临床环境中最好地实施这些技术。该项目将通过在行业、大学和医疗保健专业人员之间合作开发转换管道来解决这一问题，以支持时间关键基因组测试技术的开发和实施(专用计划)。这建立在大曼彻斯特在这一领域的世界领先声誉的基础上，使行业能够专注于其核心业务技术开发，同时学术和临床合作伙伴努力确保所述技术具有成本效益，在市场上处于有利地位，并在设计时考虑到患者。*开发一种快速基因床边测试以指导中风后患者的治疗(Genedrive plc和EMQN)。*使用新的和新兴的生物材料开发一种超快速基因测试，能够检测基因变化以指导抗生素治疗(Chromition Ltd和Epinal)。*创建一个全面的药物遗传测试小组，并提供信息解决方案，以确保在需要的时候向临床医生提供结果(APIs Assay Technologies Ltd和EMQN)。这些不同的项目将显示SPECT计划的灵活性，其成果不仅将改善人口的健康，还将创造宝贵的工业资产，从而在整个大曼彻斯特地区带来了进一步的投资。在该奖项的生命周期之后，该项目将继续与其他行业合作伙伴接触，以期在未来十年推动创新和技术转化。

A biomarker is a chemical or signal which can be measured from the human body to help to diagnose disease or predict future health states. Biomarkers are commonly used in healthcare to guide patient management, but there is a major translational bottleneck between the discovery of a clinically relevant biomarker and its implementation in routine practice to help patients. This is particularly true of genetic biomarkers, defined as changes in our genetic code which predispose to disease or predict treatment outcomes.Many of these are related to _pharmacogenetics_, the concept that changes in our genetic code influence our response to medicines. At present, genetic tests are too slow to guide prescribing in day-to-day practice. Traditional genetic tests take many weeks or months to come back, which is far too slow to be used in most clinical settings. However, new technologies have the potential to change this. The challenge for biotechnology companies is understanding how best to implement these technologies in a given clinical setting.This project will address this by developing a translational pipeline with collaboration between industry, Universities, and healthcare professionals to support the development and implementation of time critical genomic testing technologies (The DEVOTE Programme). This builds on Greater Manchester's world leading reputation in this space, empowering industry to focus on their core business of technology development, whilst academic and clinical partners work to ensure said technologies are cost effective, well placed in the market, and designed with patients in mind. DEVOTE will demonstrate its value through three exemplar projects.* Development of a rapid genetic bedside test to guide treatment for patients after stroke (Genedrive plc & EMQN).* Using new and emerging biomaterials to develop an ultra-rapid genetic test, capable of detecting genetic changes to guide antibiotic therapy (Chromition Ltd and Epinal).* Creation of a comprehensive pharmacogenetic testing panel with an informatic solution to ensure results are available to clinicians at the point of need (APIS Assay Technologies Ltd & EMQN).These varied projects will show the flexibility of the DEVOTE programme and the outputs will not only improve the health of the population, but will create valuable industrial assets, resulting in further investment across Greater Manchester. The DEVOTE programme will continue to engage with other industrial partners beyond the lifecycle of this award, with a view to drive innovation and the translation of technologies over the next decade.